

BARBADOS IS **SMALL** THE OPPORTUNITY ISN'T

Barbados has fewer than 300,000 people.

The Caribbean and Latin American market on its doorstep has around 660 million, and large parts of it are among the most import dependent in the world for essential medicines. When a supply chain fails on the other side of the world, the region feels it on its pharmacy shelves. Barbados has decided to start making its own.

Barbados Pharmaceutical Inc. (BPI) is the commercial arm of the Government of Barbados set up to make that happen. We structure the investment and partnerships behind it. In March 2026, the first IV fluids from our programme with AMA Medical Manufacturing arrived from Nigeria. Our Investment Promotion Office in Belgium connects European and global companies with opportunities in Barbados and the wider Caribbean.

STRATEGIC PRIORITIES

From dependency to sovereignty

The Caribbean often gets written off as too small and too fragmented. Yet eighteen million people across CARICOM, and almost every medicine they take is brought in from somewhere else. The region buys USD 2.8 billion of medicines a year, most of it through public tenders. What has been missing is one counterparty who can move policy, incentives, regulatory pathway and commercial terms together. That is what Barbados Pharmaceutical Inc. was set up to be. BPI works across building projects, connecting partners, and structuring the policy and financing architecture that makes the sector investable – to advance our priorities.




Attract Investment

Aligning policy, financing, and market access to give global capital a clear, credible pathway into one of the world's most underserved pharmaceutical markets.




Build Projects

Developing projects from concept to bankability to execution removing barriers, aligning stakeholders, and compressing timelines from ambition to production.



Build the Foundations

Developing the regulatory systems, workforce capacity, and research infrastructure that give partners the confidence to commit to the Caribbean long term.



Strengthen Supply Chains

Building trade corridors, coordinating procurement, and establishing the distribution infrastructure that moves essential medicines reliably, affordably, and without interruption.

WHY BARBADOS

Most pharmaceutical hubs are built on infrastructure and incentives. Barbados offers those. What makes the difference here is harder to manufacture: political will that is genuine, consistent, and globally credible.

Prime Minister, The Most Hon. Mia Mottley has positioned Barbados at the centre of the global conversation on health equity and pharmaceutical access – and backed that positioning with action. The enabling conditions are in place

Regulatory excellence for global markets

A regulator established by law, built to support pharmaceutical manufacturing and regional market access

A global market gateway

Strong local demand. **CARICOM access**. And a strategic gateway between the Americas, Africa and beyond

Incentives built for investment

50 percent R&D credit. Duty free inputs

A government on your side

A dedicated commercial partner to help move your investment **from opportunity to operation**

WHAT WE HAVE ACHIEVED

2023 · Foundation

BPI was formed and financed under the direction of the Prime Minister. Regulatory legislation was drafted, and the first partnerships were established with Rwanda, the EU, PAHO and WHO.

2024 to 2025 · Execution

Regulatory development advanced with EU and PAHO support. First manufacturer prospectus pitches completed. Governance structures and business plan launched.

In progress

Operationalising the Barbados Medical Products Authority, established in law. Launching the national sector strategy.

Groundbreaking for the first IV fluids manufacturing facility.

2025 to 2026 · Momentum

Five projects are now in active development. WHO and PAHO completed their assessment of the sector. The Minister of Health and Wellness convened an Expert Advisory Committee, and the national sector strategy was drafted. PharmaNext launched with EUR 3 million committed. The team grew from one person to fifteen, and BPI opened its Investment Promotion Office in Belgium.

PARTNER WITH US

Two years ago, there was no pharmaceutical trade corridor between Africa and the Caribbean. There is now. The regulatory authority is in formation. The first pharmaceutical manufacturing facility powered by an AU - Caribbean partnership will be built. The investment pipeline is being assembled.

This is an early moment in something significant. Partners who engage now will shape how it develops. We are looking for frontrunners, partners who are comfortable building while the ground is still being set.

We want to hear from:

- Manufacturers considering a production base in the Caribbean
- Investors looking at pharmaceutical opportunities in emerging markets
- Governments and multilateral bodies strengthening regional health supply chains
- Research and technical partners entering new markets
- Development finance institutions backing health security and trade

Or see it for yourself

Join the 2027 Barbados Trade Mission. Meet the Ministry, regulator, manufacturers and distributors shaping Barbados' pharmaceutical ecosystem.